About Us

Formulations designed in simulation, licensed to brands.

Scientific Foundations

In 2004, while pursuing his PhD at the University of Nebraska-Lincoln, Prof. Dr. Özkan Ufuk Nalbantoglu (LinkedIn, opens in a new tab) envisioned something far ahead of its time: analysing the human microbiome using artificial intelligence. At that moment, the technology to even generate such data did not yet exist.

Years later, as next-generation sequencing matured, the algorithms Prof. Nalbantoglu had developed were adopted by the Earth Microbiome Project; the world’s largest microbiome initiative. What began as a theoretical study had evolved into a globally recognised scientific infrastructure.

From 2014 onward, Prof. Nalbantoglu pushed the work further; developing algorithms not only to analyse the microbiome, but to modulate it in ways that could directly improve human health. That body of work, refined across more than fifteen years in bioinformatics and microbiome research, became the scientific foundation on which Enbiosis was built.

Portrait of Enbiosis Chief Technical Officer, in a burgundy shirt against a white background

Assoc. Prof. Özkan Ufuk Nalbantoğlu

Chief Technical Officer (CTO)

Visionary Leadership

Ömer Özkan (LinkedIn, opens in a new tab) is a serial entrepreneur and early-stage investor with an unusual appetite for high-conviction bets in deep-tech and science-led sectors. Over the past decade, he has invested across solar energy, legal technology, education, autonomous systems and healthcare; backing companies that challenge incumbents through technology rather than incrementalism.

The pivotal moment came in 2018, when Özkan met Prof. Nalbantoglu. Struck by the depth of Dr. Nalbantoğlu’s academic background and the clarity of his long-range vision, Ömer Özkan decided to build a company around microbiome science. Enbiosis was founded in 2019, and from then on, Özkan closed every other chapter of his career to dedicate himself to one mission: turning microbiome science into a global health company.

Ömer Özkan

Chief Executive Officer (CEO)

What We Do

Formulation design and licensing

Enbiosis uses its Digital Twin & AI Powered Nutraceutical Formulation Engine to model the gut microbiome and design condition-specific, food-grade nutraceutical formulations, which it licenses to OTC, supplement, food and beverage brands.

How licensing works

Enbiosis formulations are licensed under the “Powered by Enbiosis” framework. The ingredients are food-grade and can be built into capsules and powders, or offered alongside functional foods, drinks and dairy products. Licences are granted by formulation, category and territory, with exclusivity available.

The en- formulations

The en- family is Enbiosis’s own line of products, which it calls smart supplements, each built on a gut-organ axis. en-TEAR, built on the gut-eye axis, is on sale in Türkiye. en-JOY&FIT (metabolic health), en-CLEAR (skin health) and en-MASCULINE (men’s health) are in development and open to licensing.

Research record: peer-reviewed and registered

Our scientific approach is led by a multidisciplinary team combining computational modeling with clinical expertise. Dr. Ufuk Nalbantoğlu (CTO) leads our digital twin–based modeling, while Varol Tunalı, MD, PhD, oversees clinical strategy and study management, and Beyza Hilal Ermiş, MSc leads clinical nutrition. This structure is supported by experts in bioinformatics, clinical operations, and data science, enabling the team to translate microbiome science into formulation design. The team’s studies are published in peer-reviewed journals and registered on ClinicalTrials.gov.

Our research record includes six peer-reviewed articles. Four are clinical publications on an AI-assisted personalised diet approach, including two randomised controlled trials. These studies and their data underpin the Digital Twin & AI Powered Nutraceutical Formulation Engine. Enbiosis formulations are being studied separately: randomised studies are registered on ClinicalTrials.gov in six health areas and are ongoing; their results will be shared when the studies are completed.

The American Journal of Gastroenterology (2024)
A Multicenter Randomized Controlled Trial of Microbiome-Based Artificial Intelligence-Assisted Personalized Diet vs Low-Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols Diet: A Novel Approach for the Management of Irritable Bowel Syndrome.
Gut Microbes (2026)
Long-term microbiome and clinical effects of a microbiome-guided personalized diet versus low-FODMAP diet in irritable bowel syndrome: A 12-month follow-up randomized controlled trial.
Gut Microbes (2022)
Artificial intelligence-based personalized diet: A pilot clinical study for irritable bowel syndrome.
Journal of Clinical Medicine (2022)
Efficacy of AI-Assisted Personalized Microbiome Modulation by Diet in Functional Constipation: A Randomized Controlled Trial.
Molecular Nutrition & Food Research (2024)
A Shotgun Metagenomics Investigation into Labeling Inaccuracies in Widely Sold Probiotic Supplements in the USA
Biomedical Signal Processing and Control (2025)
Deep learning-enhanced wellness scores: a population-level study on gut microbiome profiling and health prediction.

The Nutraceutical Formulation Engine

Each Enbiosis formulation is condition-specific and designed in the Digital Twin & AI Powered Nutraceutical Formulation Engine.

The engine models the gut microbiome, identifies the metabolic pathways linked to the target health area, and works backwards from a target metabolite to the minimal set of food-grade ingredients that gut bacteria can convert into it. Combinations are simulated with digital twin technology, and the selected formulation is evaluated in clinical studies.

Dotted illustration of a human figure with the gut highlighted, surrounded by microorganism and DNA motifs

Gut microbiome model

Digital Twin & AI Powered Nutraceutical Formulation Engine

Gut microbiome model

Digital Twin & AI Powered Nutraceutical Formulation Engine

The approach works with the gut microbiome already present: a formulation supplies food-grade inputs that gut bacteria can convert into target metabolites.

Breadth of application

The engine can model a wide range of health areas with a well-characterised gut microbiome link. Six are in ongoing, registered clinical study today: eye, metabolic, weight management, gastrointestinal, skin and men’s health. Further areas will be added here as their studies are registered.

Clinical Results: Validated Success, Promising Signals

Dry eye

In the en-TEAR pilot (single-arm, open-label, n=20), tear production at 16 weeks rose 67% from baseline (Schirmer test, 10.0 to 16.7 mm), eight weeks after intake had stopped. The article has been submitted for peer review and reports every secondary endpoint, including those that did not reach significance.

tear production at week 16, eight weeks after intake had stopped: +67%
Schirmer test, baseline to week 16: 10.0 to 16.7 mm

Prospective, single-arm, open-label pilot · 8-week intervention & 8-week post-intervention follow-up · n=20

Blood Glucose Control

Our latest pilot showed a promising early signal: en-JOY&FIT was associated with a meaningful shift in blood glucose control over twelve weeks, with both fasting glucose and HbA1c moving in a healthier direction. The same formulation is now being tested in two ongoing randomized, placebo-controlled trials, one in blood glucose regulation and one in weight management, to establish causality and durability.

Baseline

Fasting glucose · mean

142.0mg/dL

HbA1c · mean

7.6%

After 12 weeks

Fasting glucose · mean

117.8mg/dL

−24.2 mg/dL · p<0.001 · average reduction

HbA1c · mean

6.9%

−0.75 points · p<0.001

HbA1c: −0.91 points excluding 1 discordant case.

Fasting glucose improved in 21 of 25 participants with paired labs.: 84%
HbA1c improved in 22 of 25. The single case that worsened rose discordantly even as its fasting glucose fell.: 88%

Single-arm, open-label pilot · 12-week intervention · n=25

Recognition & Achievements

Enbiosis has been recognised by some of the most respected institutions and programmes in European deep tech and life sciences:

UK Tech Rocketship Awards
Gold Medal · 2022
Awarded by the UK government (Department for Business and Trade) as one of the most promising technology companies from outside the UK; a flagship programme that effectively opened our UK market entry.
Sanofi
Country Winner · 2022
Probiota Americas
Scientific Frontiers Winner · 2023
NutraIngredients Awards
Finalist · 2023
Finalist for Product of the Year: Microbiome Modulation. The leading European award in the nutraceutical and functional-food industry.
UK Department for International Trade recognition
Enbiosis was named one of the best technology companies across Europe (including Israel) at time of assessment.
Digestive Disease Week & IFM International Conference
Invited presentations of the multicentre IBS study, 2023.

Together, these recognitions mark Enbiosis as an internationally recognised company in Digital Twin & AI Powered nutraceutical formulation, with a research record published in peer-reviewed journals and registered on ClinicalTrials.gov.

Product family labelled Powered by Enbiosis: a bottle, jars, a sachet and a tube

Where we go from here

Every Enbiosis formulation is simulated with digital twin technology and evaluated in clinical studies before launch. Our registered studies are ongoing, and their results will be shared when they are completed.

OTC, supplement, food and beverage brands license Enbiosis formulations under the “Powered by Enbiosis” framework and offer them in or alongside their own products.